|
|
Article: Sigma-Aldrich[R] and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement.
- Article from:
- Vaccine Weekly
- Article date:
- October 21, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Sigma-Aldrich Corporation (NASDAQ:SIAL) and Sangamo BioSciences, Inc. (NASDAQ:SGMO) announced a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights to certain ZFP-engineered transgenic animals for commercial applications (see also Biotech Business).
"The zinc finger technology platform developed by Sangamo is a core component of Sigma-Aldrich's growth strategy into high-value biologic tools," said Jai Nagarkatti, Sigma-Aldrich's Chairman, President and ...